Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $49.33 Consensus PT from Brokerages
Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) has been given an average rating of “Buy” by the seven ratings firms that are covering the firm, Marketbeat.com reports. Seven analysts have rated the stock with a buy recommendation. The average 12 month price target among brokers that have issued ratings on the stock in the […]
Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) has been given an average rating of “Buy” by the seven ratings firms that are covering the firm, Marketbeat.com reports. Seven analysts have rated the stock with a buy recommendation. The average 12 month price target among brokers that have issued ratings on the stock in the […]
